Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$4.26-0.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · IRWD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Annual board election with no specific departures or appointments mentioned.
Other Events. On June 15, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 (the “2026 Convertible Notes”) at their scheduled maturity. The Company funded the repayment of the outstanding aggregate principal amount of the 2026 Convertible Notes using proceeds from available cash on hand. No conversions were exercised by holders of the 2026 Convertible Notes, and the capped call trans…
interim chief financial officer and principal financial officer — Mr. Silver: Mr. Silver was promoted to interim chief financial officer and principal financial officer.
Chief Financial Officer — Gregory Martini: Mr. Martini resigned from his position as Senior Vice President, Chief Financial Officer.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Other Events. On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement, dated May 21, 2023, as amended by Amendment No. 1 to Credit Agreement, dated September 27, 2024 (the “Amended Credit Agreement,” and collectively, the “Credit Agreement”), by and among the Company, as borrower, the Agent and the other agents, lenders and letter of credit issuers par…
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. Amendment to License Agreement with Ferring On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the “Company”), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company (“VectivBio”), and Ferring International Center S.A. (“Ferring”), entered into that certain third amendment (the “Amendment”) to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and…
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Director — Andrew Dreyfus: Mr. Dreyfus resigned to take a new role as President and CEO of NIHCM Foundation.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On July 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm. The Audit Committee made its decision after soliciting and reviewing competitive proposals from independent registered public accounting firms, includi…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 28, 202 5, Ironwood Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) had closed below the $1.00 per…
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Regulation FD Disclosure. On March 27, 2025, the Company issued a press release in accordance with Nasdaq Listing Rule 5810(b) announcing that the Company had received the Notice. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 21, 202 5, Ironwood Pharmaceuticals, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) with the Securities and Exchange Commission (…
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Chief Financial Officer (CFO) — Gregory Martini: Gregory Martini was promoted to Senior Vice President, Chief Financial Officer.
Costs Associated with Exit or Disposal Activities. Following an analysis of Ironwood Pharmaceuticals, Inc.’s (the “Company”) strategy and core business needs, and in an effort to streamline focus and support the continued development of the Company’s pipeline, on January 17, 2025, the Board of Directors of the Company approved a reduction in the Company’s workforce of approximately 50%, primarily consisting of field-based sales employees. Affected employees were notified on January 29, 2025.…
Senior Vice President, Chief Operating Officer and Chief Financial Officer — Sravan K. Emany: Mr. Emany is resigning from his positions without a named successor, leading to an interim arrangement.
Senior Vice President, Chief Business Officer — Andrew Davis: Andrew Davis is resigning from his position as Senior Vice President, Chief Business Officer.
of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.